{"cluster": 36, "subcluster": 39, "abstract_summ": "In this study we find that critically-ill patients with COVID-19 robustly upregulate constituents of the extrafollicular pathway, produce enormous numbers of antibody secreting cells, and lose unique transitional B cell populations that correlate with positive prognosis.Also of note, EF B cell activation is particularly prominent in SLE patients of African-American ancestry, a population disproportionately represented in severe COVID-19.In this systemic autoimmune disease, the EF pathway is initiated by newly activated naive B cell (aN) leading to large expansion of autoantibody-producing antibody-secreting cells through the generation of an epigenetically primed B cell precursor which are double negative (DN) for naive (IgD) and memory markers (CD27) and lacking expression of CXCR5 and CD21 (DN2).Thus, this B cell phenotype might serve as an immunological marker of severe COVID infection at early stages and could therefore identify a patient subset likely to benefit from targeted immunomodulatory therapy aimed at alleviating disease burden.Systems-level analyses are required to simultaneously capture all immune cell populations and the many protein mediators by which cells communicate.", "title_summ": "Systems-level immunomonitoring from acute to recovery phase of severe COVID-19Immune alterations during SARS-CoV-2-related acute respiratory distress syndromeComplex Immune Dysregulation in COVID-19 Patients with Severe Respiratory FailureCritically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation", "title_abstract_phrases": "In this study we find that critically-ill patients with COVID-19 robustly upregulate constituents of the extrafollicular pathway, produce enormous numbers of antibody secreting cells, and lose unique transitional B cell populations that correlate with positive prognosis.Also of note, EF B cell activation is particularly prominent in SLE patients of African-American ancestry, a population disproportionately represented in severe COVID-19.In this systemic autoimmune disease, the EF pathway is initiated by newly activated naive B cell (aN) leading to large expansion of autoantibody-producing antibody-secreting cells through the generation of an epigenetically primed B cell precursor which are double negative (DN) for naive (IgD) and memory markers (CD27) and lacking expression of CXCR5 and CD21 (DN2).We also map an immune trajectory during recovery that is shared among patients with severe COVID-19.Immune alterations during SARS-CoV-2-related acute respiratory distress syndromeWe report a longitudinal analysis of the immune response associated with a fatal case of COVID-19.Thus, this B cell phenotype might serve as an immunological marker of severe COVID infection at early stages and could therefore identify a patient subset likely to benefit from targeted immunomodulatory therapy aimed at alleviating disease burden."}